Pollen-food allergy syndrome: An overview
Journal of Food Allergy · 2026-10-01 · 8 (2) · 84-91
DOI: 10.2500/jfa.2026.8.260009 ↗Abstract
Background: Pollen-food allergy syndrome (PFAS), a common allergic condition that typically features oropharyngeal pruritus, results from primary sensitization to tree, grass, or weed pollen, and subsequent cross-reactivity to homologous food allergens. Recent literature that evaluated the properties of culprit cross-reactive allergens has enhanced our understanding of the pathophysiology and clinical features of the syndrome, while additional research has evaluated novel therapeutic approaches. Objectives: The objectives were the following: (1) review the epidemiology, pathophysiology, and clinical presentation of PFAS; (2) discuss the diagnostic evaluation for PFAS; and (3) discuss the management of PFAS. Methods: This review discusses recent literature that evaluated PFAS epidemiology, pathophysiology, diagnostic evaluation, and management. Results: Although symptoms of PFAS are typically benign and limited to the oropharynx, systemic symptoms are possible, for which several risk factors have been identified. The diagnosis is typically made by careful review of the clinical history and demonstration of relevant inhalant allergen sensitization; however, a more-extensive diagnostic evaluation may be required for patients with discrepant clinical histories or previous systemic reactions. Management strategies have historically included counseling on the risk of systemic reactions, consideration for avoidance of the offending foods, and consideration for carrying an epinephrine autoinjector for those at greater risk of systemic reactions; however, recent studies have explored alternative treatments, including the use of food and pollen immunotherapy and biologics. Conclusion: Risk stratification, patient education, and shared decision-making are essential to guide the management of PFAS. Further research is required to establish the efficacy of inhalant allergen and food immunotherapy in the treatment of PFAS.
EUVIMED